Formoterol Fumarate Dihydrate
Basic Information
| Item | Value |
|---|---|
| DrugBank ID | DB00983 |
| Evidence Level | L5 (Computational Prediction) |
| Number of Predicted Indications | 20 |
Predicted Indications (TxGNN)
The following are potential new indications predicted by the TxGNN model. Higher scores indicate higher predicted relevance.
| # | Indication | Source |
|---|---|---|
| 1 | respiratory malformation | KG + DL |
| 2 | bronchitis | KG + DL |
| 3 | Rienhoff syndrome | KG + DL |
| 4 | obstructive lung disease | KG + DL |
| 5 | asthma | KG + DL |
| 6 | asthma-related traits, susceptibility to | KG + DL |
| 7 | atopic eczema | KG + DL |
| 8 | hyperlucent lung | KG + DL |
| 9 | compensatory emphysema | KG + DL |
| 10 | interstitial emphysema | KG + DL |
| 11 | chronic obstructive pulmonary disease | KG + DL |
| 12 | bronchial neoplasm (disease) | KG + DL |
| 13 | tracheal stenosis | KG + DL |
| 14 | COPD, severe early onset | KG + DL |
| 15 | susceptibility to respiratory infections associated with CD8alpha chain mutation | KG + DL |
| 16 | congenital lobar emphysema | KG + DL |
| 17 | supravalvular aortic stenosis (disease) | KG + DL |
| 18 | tracheal calcification | KG + DL |
| 19 | 2-hydroxyethyl methacrylate sensitization | KG + DL |
| 20 | cough variant asthma | KG + DL |
Disclaimer
These predictions are for research purposes only and do not constitute medical advice. Clinical validation is required before any clinical application.